IL6 and acute graft versus host disease: IL-6 is also considered a potential biomarker of acute GVHD after allogeneic HSCT, and elevated IL-6 levels have been shown to be significantly associated with worse outcomes, including severe cytokine release syndrome (CRS) and acute GVHD, and decreased overall survival [31,32].